Ireland - English - HPRA (Health Products Regulatory Authority)

eumedica pharmaceuticals gmbh - buprenorphine hydrochloride - solution for injection - oripavine derivatives; buprenorphine

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - thrombin; factor xiii; calcium chloride; fibrinogen; aprotinin -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

gowan crop protection australia pty ltd - quinoxyfen - suspension concentrate - quinoxyfen quinoline-phenoxy active 250.0 g/l - fungicide - grapevine - powdery mildew on grapevine

Israel - English - Ministry of Health

novartis israel ltd - secukinumab - powder for solution for injection - secukinumab 150 mg/dose - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.- paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.- psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate.- axial spondyloarthritis (axspa) :• ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.• non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids).- juvenile idiopathic arthritis (jia)• enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. • juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - secukinumab - injection, powder, for solution - secukinumab 150 mg/vial

United Kingdom - English - myHealthbox

boehringer ingelheim international gmbh - tiotropium (as bromide monohydrate), olodaterol (as hydrochloride) - inhalation solution - 2.5 microgram/2.5 microgram per puff - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 100 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 150 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - aprotinin 2250 kiu/ml - 3750 kiu/ml; factor xiii 1.2 iu/ml - 10 iu/ml; fibrinogen 72 mg/ml - 110 mg/ml; calcium chloride dihydrate 0.036 mmol/ml - 0.044 mmol/ml; thrombin 3.2 iu/ml - 5 iu/ml - topical solution - 4 iu - active: aprotinin 2250 kiu/ml - 3750 kiu/ml factor xiii 1.2 iu/ml - 10 iu/ml fibrinogen 72 mg/ml - 110 mg/ml excipient: albumin histidine nicotinamide polysorbate 80 sodium citrate dihydrate water for injection active: calcium chloride dihydrate 0.036 mmol/ml - 0.044 mmol/ml thrombin 3.2 iu/ml - 5 iu/ml excipient: albumin sodium chloride water for injection - artiss is indicated for use in adhering autologous skin grafts in burn patients. artiss is not indicated for haemostasis.

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - methylphenidate hydrochloride 10 mg - tablet